NASDAQ · DRTS
Healthcare · Biotechnology
$12.83
Up+$0.71 (+5.53%)
Updated Nov 3, 2026, 9:44 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DRTS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
DRTS closed at $12.83 after 21 trading sessions, down 13.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $13.22 | $13.25 | $12.67 | $12.83 | 437.37K |
| Oct 30, 2026 | $12.85 | $13.145 | $12.7025 | $13.06 | 475.32K |
| Oct 29, 2026 | $13.31 | $13.55 | $13.055 | $13.23 | 293.56K |
| Oct 28, 2026 | $13.51 | $13.62 | $13.25 | $13.35 | 401.57K |
| Oct 27, 2026 | $12.99 | $13.66 | $12.71 | $13.51 | 342.11K |
| Oct 26, 2026 | $13.18 | $13.5552 | $12.77 | $12.89 | 379.08K |
| Oct 23, 2026 | $12.75 | $13.25 | $12.70 | $13.16 | 324.81K |
| Oct 22, 2026 | $13.25 | $13.46 | $12.71 | $12.90 | 447.71K |
| Oct 21, 2026 | $13.47 | $13.85 | $13.30 | $13.48 | 500.32K |
| Oct 20, 2026 | $12.61 | $13.383 | $12.50 | $13.09 | 833.54K |
| Oct 19, 2026 | $12.56 | $12.8099 | $12.42 | $12.62 | 688.39K |
| Oct 16, 2026 | $13.24 | $13.30 | $11.99 | $12.29 | 778.85K |
| Oct 15, 2026 | $13.14 | $13.4697 | $13.02 | $13.16 | 620.39K |
| Oct 14, 2026 | $13.48 | $13.7879 | $13.3354 | $13.50 | 422.39K |
| Oct 13, 2026 | $14.11 | $14.25 | $13.6501 | $13.74 | 484.82K |
| Oct 12, 2026 | $14.42 | $14.44 | $14.11 | $14.26 | 281.47K |
| Oct 9, 2026 | $14.00 | $14.50 | $13.98 | $14.41 | 368.2K |
| Oct 8, 2026 | $14.17 | $14.295 | $13.56 | $14.00 | 595.44K |
| Oct 7, 2026 | $14.27 | $14.44 | $14.10 | $14.25 | 466.37K |
| Oct 6, 2026 | $14.975 | $15.02 | $14.40 | $14.48 | 427.52K |
| Oct 5, 2026 | $14.85 | $15.0399 | $14.68 | $14.89 | 342.44K |
The latest Smart Investors Daily articles mentioning DRTS.
Company
Market Activity
Research & News
DRTS research
Company profile and research snapshot.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 3, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 22, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea, with Samsung
Benzinga · Oct 20, 2026
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
Benzinga · Oct 19, 2026
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has
SeekingAlpha · Sep 4, 2026
Discover Alpha Tau (DRTS) ahead of pivotal GBM and pancreatic cancer data.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DRTS.
